MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Synucleinopathies"

  • 2016 International Congress

    Colonic α-synuclein: A potential diagnostic biomarker in Parkinson’s disease

    C. Ruffmann, I. Poggiolini, N. Bengoa-Vergniory, F. Baig, M. Rolinski, J. Klein, M.T. Hu, R. Wade-Martins, J. Alegre-Abarrategui, L. Parkkinen (Oxford, United Kingdom)

    Objective: To validate detection of α-synuclein pathology in the gastrointestinal (GI) tract as a diagnostic marker of Parkinson's disease (PD). Background: α-synuclein (ASN) deposition in…
  • 2016 International Congress

    Unconventional chaperone inhibits alpha-synuclein amyloid formation by promoting off-pathway aggregation

    J. Bieschke, E. Illes-Toth, M. Shah, N. Wu, S. Verzini, P. Selenko, E. Wanker (Saint Louis, MO, USA)

    Objective: To find new potential druggable targets that prevent alpha-synuclein aggregation and toxicity in Parkinson's disease. Background: Alpha-synuclein (aS) is the primary protein deposited in…
  • 2016 International Congress

    Factors affecting the cardiac sympathetic denervation in autopsy confirmed dementia with Lewy bodies

    M. Takahashi, T. Uchihara, M. Yoshida, K. Wakabayashi, A. Kakita, H. Takahashi, S. Toru, T. Kobayashi, S. Orimo (Tokyo, Japan)

    Objective: To examine the relation among degeneration of the cardiac sympathetic nerve (CSN), clinical features and neuropathological findings in dementia with Lewy bodies (DLB). Background:…
  • 2016 International Congress

    Pre-formed fibrils injection worsen pathology caused by AAV-mediated over expression of α-synuclein

    L.S. Breger, P. Thakur, O.W. Wan, B. Mattsson, K. Luk, V.M. Lee, J. Trojanowski, A. Björklund (Lund, Sweden)

    Objective: The overall goal is to produce a rat model of Parkinson's disease (PD), which reproduces progressive pathological changes, while displaying profound neuronal cell loss…
  • 2016 International Congress

    The unfolded protein response pathway as a possible therapeutic target for the synucleinopathies

    J.H. Baek, E. Bereczki, D. Aarsland (Stockholm, Sweden)

    Objective: To investigate whether the pharmacological inhibition of unfolded protein response (UPR) pathway would be beneficial in cellular model of synucleinopathies. Background: It has been…
  • 2016 International Congress

    Identification of Usp8 as a toxicity modifying deubiquitinase for α-synuclein

    Z. Alexopoulou, J. Lang, R. Perrett, H.T. Kim, A.L. Goldberg, O. Ansorge, T.A. Fulga, G.K. Tofaris (Oxford, United Kingdom)

    Objective: To study whether ubiquitination in Lewy bodies is directly relevant to α-synuclein turnover and Parkinson's pathogenesis. Background: In Parkinson's disease, misfolded α-synuclein accumulates, often…
  • 2016 International Congress

    Human-derived α-synuclein antibody BIIB054 binds pathologic forms of α-synuclein and attenuates transmission of α-synuclein in vitro and in vivo

    A. Weihofen, H. Patel, C. Huy, C. Liu, I. Combaluzier, S. Mueller-Steiner, N. Cavegn, L. Strobel, T.M. Engber, K.J. Rhodes, C. Hock, R.M. Nitsch, F. Montrasio, J. Grimm, A. Dunah, P.H. Weinreb (Cambridge, MA, USA)

    Objective: To identify and characterize a human antibody against α-synuclein (α-syn) for the clinical development of an immunotherapy for Parkinson's disease (PD). Background: α-syn plays…
  • 2016 International Congress

    Cell-surface expression of dopamine transporter facilitates the uptake of α-synuclein

    J. Kobayashi, T. Hasegawa, S. Yoshida, N. Sugeno, R. Oshima, A. Kikuchi, A. Takeda, M. Aoki (Sendai, Japan)

    Objective: We determined whether increased expression of DAT have an impact on the uptake of α-synuclein (αS). Background: The endocytosis of dopamine transporter (DAT) controls…
  • 2016 International Congress

    Novel small molecules targeting alpha-synuclein aggregation for the treatment of Parkinson’s disease

    E. Tsika, A. Davranche, E. Gabellieri, S. Nampally, J. Molette, S. Papin, H. Kroth, A. Pfeifer, D. Lowe, A. Muhs (Lausanne, Switzerland)

    Objective: To develop novel, small molecular weight compounds, that can interfere with the aggregation process of alpha-synuclein (aSyn), as disease modifying agents. Background: The aggregation…
  • 2016 International Congress

    Modulation of microglia function in the prion-like spreading of α-synuclein in the murine brain

    W.M. Wemheuer, P. Garcia, E. Konica, A. Masuch, S. Brioschi, K. Biber, A. Weihofen, H. Kollmus, K. Schughart, D. Coowar, R. Balling, M. Buttini (Esch-sur-Alzette, Luxembourg)

    Objective: We aimed to analyze the influence of two microglia-related pathways on the accumulation of α-synuclein aggregates and neurodegeneration after intracerebral injection of sonicated murine…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley